KPV for Inflammation: What the Evidence Shows
What human and animal studies show about KPV for inflammation, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Animal
- Human studies
- 10
- PubMed records, our ledger
- Animal studies
- 19
- PubMed records, our ledger
- Studies we summarised
- 6
- with an outcome for inflammation
Evidence for inflammation
Each row is an outcome related to inflammation from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| DSS colitis recovery | KPV-treated mice recovered earlier and regained more body weight in DSS colitis. | Animal · mouse (not a human result) | Inflammatory bowel diseases 2008, PMID 18092346 |
| Survival in MC1R-nonfunctional mice | KPV treatment rescued all treated MC1R-nonfunctional mice from death during DSS colitis. | Animal · mouse (not a human result) | Inflammatory bowel diseases 2008, PMID 18092346 |
| Colitis incidence (oral KPV) | Oral KPV in drinking water reduced the incidence of DSS- and TNBS-induced colitis in mice and lowered inflammatory cytokine expression. | Animal · mouse (plus human intestinal epithelial and T cell lines) (not a human result) | Gastroenterology 2008, PMID 18061177 |
| Peritonitis (neutrophil accumulation) | KPV reduced inflammatory cell accumulation in mouse peritonitis through a mechanism distinct from other melanocortin peptides. | Animal · mouse (not a human result) | The Journal of pharmacology and experimental therapeutics 2003, PMID 12750433 |
| Fever | The tripeptide reduced fever in rabbits after central (0.5-2.0 mg) and peripheral (2-200 mg) administration. | Animal · rabbit (not a human result) | Peptides 1984, PMID 6333677 |
| Keratinocyte viability and IL-1beta | KPV at 50 ug/mL restored cell viability and reduced IL-1beta secretion in PM10-exposed keratinocytes. | In vitro (not a human result) | Tissue & cell 2025, PMID 40073467 |
| Airway epithelial inflammatory signalling | KPV dose-dependently inhibited NF-kB signalling, MMP-9 activity, and IL8 and eotaxin secretion in cultured airway cells. | In vitro (not a human result) | International journal of physiology, pathophysiology and pharmacology 2012, PMID 22837805 |
PubMed records for KPV and inflammation: 10 human, 19 animal (search counts, not studies we reviewed). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
What inflammation looks like
MedlinePlus explains that redness, swelling, heat and pain are the signs and symptoms of inflammation, and that many autoimmune diseases cause them.[7]
Inflammation models where KPV has been tried
In a mouse model of crystal-induced peritonitis, the authors concluded KPV is unlikely to act through melanocortin receptors and more likely acts through inhibition of IL-1beta functions.[3]
In human bronchial epithelial cells grown in a dish, KPV dose-dependently inhibited NF-kB signalling and release of IL-8 and eotaxin; this is a cell line, not a patient.[6]
In rabbits, the tripeptide reduced fever after both central (0.5-2.0 mg) and peripheral (2-200 mg) administration.[4]
In mouse colitis, KPV cut inflammatory infiltrates and an enzyme marker of inflammation in colon tissue.[1]
In human keratinocytes exposed to fine dust, KPV at 50 μg/mL reduced IL-1β release; this is again a cell-culture result.[5]
Counts and limits
The inflammation PubMed query for KPV (run 2026-10-02) found 29 human-tagged records (10 human-only), 19 animal records and 0 randomized trials among 56 in all.
Calculated from human 29; human only 10; animal 19; rct 0; all 56. Formula: Counts copied from the kpv ledger row of the inflammation goal in goals.json; no arithmetic.
Of the 9 KPV papers we hold, 0 recruited participants, so every inflammation result above comes from animals or cultured cells.
Calculated from kpv studies in evidence file 9; human participant studies 0. Formula: Study designs counted from web/src/data/evidence/kpv.json (animal, in-vitro); no arithmetic.
Other peptides people research for inflammation
All peptides for inflammation, comparedCommon questions
Does KPV help with inflammation?
The strongest study we summarise for inflammation is animal evidence, across 6 studies with an outcome for inflammation. That is not proof it works in people.
Is KPV approved for inflammation?
No. KPV is not FDA approved for any use, including inflammation.
What is the best peptide for inflammation?
There is no single answer. Our inflammation overview compares each candidate by evidence grade and legal status rather than by popularity.
Is KPV anti-inflammatory?
In mice and cell cultures it reduced inflammatory markers; no trial has tested it in people with an inflammatory disease.[1]
How does KPV reduce inflammation?
A mouse peritonitis paper concluded KPV is unlikely to act through melanocortin receptors and more likely acts through inhibition of IL-1beta functions.[3]
Is there a KPV anti-inflammatory dose?
No human dose is cited here. The only dose figures are from rabbit fever work: 0.5-2.0 mg centrally and 2-200 mg peripherally.[4]
More on KPV
Sources
- 1Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.Inflammatory bowel diseases · 2008PMID 18092346Accessed 2 Oct 2026
- 2PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.Gastroenterology · 2008PMID 18061177Accessed 2 Oct 2026
- 3Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.The Journal of pharmacology and experimental therapeutics · 2003PMID 12750433Accessed 2 Oct 2026
- 4Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit.Peptides · 1984PMID 6333677Accessed 2 Oct 2026
- 5Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway.Tissue & cell · 2025PMID 40073467Accessed 2 Oct 2026
- 6Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.International journal of physiology, pathophysiology and pharmacology · 2012PMID 22837805Accessed 2 Oct 2026
- 7medlineplus.gov pagemedlineplus.gov · web pagemedlineplus.gov
Found an error? Report a correction.